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2 
Vorbemerkung / Preliminary Remarks 
 
 
The following synopsis serves the purpose to summarize the peer-reviewed publication 
that I contribute to the scope of my thesis. The structure and extent of the synopsis 
follows the regulations of the Medizinischen Fakultät, Universität Leipzig. For detailed 
introduction, methods, results and discussion please see the publication (Schwind et al. 
J Clin Oncol. 2010 Dec 20; 28(36): 5257-64) and the supplemental material, which are 
inserted in their complete form in section ‘Publication’, starting on page 13. 
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Referat / Abstract 
 
Despite advances in the understanding of cancer biology, most patients with acute 
myeloid leukemia (AML) still die of their disease. Improving risk-stratification and 
identifying new targets are important steps towards personalized medicine and outcome 
improvement. MicroRNAs, short non-coding RNAs that hybridize to their target 
messenger RNAs (mRNAs) and repress the expression of the encoded proteins, are 
known to be involved in physiological processes like cellular differentiation, proliferation 
and cell survival but also play an essential role in cancer, including AML. 
In this thesis we demonstrated that higher expression of a single microRNA 
- miR-181a - was associated with clinical outcome in cytogenetically normal AML 
(CN-AML) patients. In multivariable models, higher expression of miR-181a was 
associated with achievement of complete remission (CR), with longer disease-free 
(DFS) and overall survival (OS) even in consideration of other validated prognostic 
clinical and molecular variables. Measurement of pretreatment levels of this microRNA 
may improve risk-stratification for AML patients. A genome-wide gene-expression 
signature gave biological insights into miR-181a associated AML, and provides a basis 
for further functional studies. Furthermore, as higher miR-181a expression associated 
with improved treatment response, increasing miR-181a levels by delivering synthetic 
miR-181a or by agents increasing endogenous levels of this microRNA in AML blasts 
may represent a novel and personalized therapeutic approach in AML. 
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Einführung / Introduction 
 
Acute myeloid leukemia (AML) belongs to the most common malignant hematological 
disorders with a median age at diagnosis in the late 60’s.1,2 The disease is characterized 
by uncontrolled proliferation of hematopoietic progenitor cells and a differentiation block 
in bone marrow and blood. AML presents itself cytogenetically and molecularly 
heterogeneous.3-7 Despite recent progress in deciphering the biology of the disease and 
advances in the development of new investigational therapies, the outcome of most 
AML patients remains vastly improvable.8,9  
 
Determination of the best therapy for individual patients remains an every-day challenge 
for clinicians. Today, specific clinical, cytogenetic and molecular prognosticators for 
outcome may be used as tools to provide the physician with objective information which 
may aid in the task of making informed treatment decisions.7-10 Such information allows 
decisions on intensification or de-escalation of therapy, enrollment in studies testing 
new agents or experimental treatment approaches, as well as on the appropriateness of 
an allograft procedure in first complete remission (CR) with its consequent treatment-
related morbidity, mortality and financial costs.  
 
Among the strongest prognostic factors in AML are chromosomal aberrations (i.e. 
numerical or structural abnormalities) within the malignant clones.3 An abnormal 
karyotype is observed in approximately 60% of AML patients and certain abnormalities 
are highly associated with outcome, following today’s standard of care.3,4 Since these 
5 
cytogenetic changes are associated with outcome of AML patients they are used to 
assign patients to certain risk categories (Table 1).3,4  
 
Table 1: Adapted from Fröhling et al.;4 Cytogenetic Classification Systems used to define prognostic 
groups in the respective cooperative groups (MRC, Medical Research Council; SWOG/ECOG, Southwest 
Oncology Group/Eastern Cooperative Group; CALGB, Cancer and Leukemia Group B [did not include 
t(15;17)]). 
 





























































Even though for some of these abnormalities the assigned risk is lacking agreement 
among the cooperative groups [e.g. the risk associated with del(5q) or del(9q)], some 
general statements can be derived (Table 1).  
 
About 25% of AML cases that arise in younger adults will have cytogenetic 
abnormalities associated with favorable outcome.3 These are i.e. the translocation 
t(15;17)(q22;q21) in acute promyelocytic leukemia (APL) and the core-binding factor 
(CBF) leukemias inv(16)(p13q22) / t(16;16)(p13;q22) and t(8;21)(q22;q22).3,4,10 Such 
favorable karyotype patients have a good prognosis with CR rates exceeding 90%, a 
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5-year survival of at least 65% and relapse rates too low and salvage rates too high to 
benefit from routine use of an allograft in first CR.11-17  
 
On the other hand, in about 10–20% of patients with AML so called adverse 
cytogenetics are found. They typically include monosomies of chromosome 5 and/or 7 
(−5/−7), abnormalities of 3q [abn(3q)] or complex karyotypes. The definition of the latter 
ones is based on the presence of at least three (or five) unrelated cytogenetic 
abnormalities according to different cooperative groups (Table 1).3,4 In general, these 
patients can expect CR rates of approximately 60% and a 5-year survival as low as 
10%.3,4 Due to the very poor prognosis with current standard therapies, an allograft 
procedure in first CR or an experimental treatment approach may be justified.3,4 
 
These risk classifications show that cytogenetic information is important for informed 
decisions on appropriate treatment strategies. However, for some AML patients, 
cytogenetic analysis may not be sufficient for risk-adapted stratification. For example, 
approximately 40% of the patients with AML harbor a normal karyotype with no 
numerical or structural abnormalities [cytogenetically normal (CN)-AML].3,4 But despite 
the homogeneous chromosomal appearance, and their general association with an 
intermediate risk, this group of patients presents with a very heterogeneous clinical 
outcome.3,4  
 
Within the past years, in addition to karyotype information, the presence or absence of 
certain recurrent gene mutations have been proven very helpful in further refining the 
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risk-classifications of AML patients. A growing body of evidence suggests that two gene 
mutations in AML are representing primary genetic lesions in the disease: mutations in 
the NPM1 (nucleophosmin 1) gene and in the CEBPA [CCAAT/enhancer binding 
protein (C/EBP), alpha] gene have been recognized as two new provisional entities by 
the World Health Organization (WHO).10 Mutations in a third gene, coding for the fms-
related tyrosine kinase 3 (FLT3) are found in many AML subtypes and are believed to 
confer to a proliferation and/or survival advantage of the myeloid blasts. AML with FLT3 
mutations are not considered a distinct entity, but the WHO recommends determining 
the presence of such mutations due to their prognostic significance.10 Today these three 
mutations are recommended for assessment in newly diagnosed AML cases for 
standard risk stratification.  
 
Following these recommendations, recently an expert panel on behalf of the European 
LeukemiaNet (ELN) suggested a standardized reporting system for genetic 
abnormalities.11 This reporting system includes data from cytogenetic analysis and from 
the mutation analysis of the three aforementioned genes (i.e. NPM1, CEBPA and 
FLT3).11 The guidelines are classifying AML in four genetic groups according to this 









Table 2: Adapted from Döhner et al.;11 standardized reporting for correlation of cytogenetic and molecular 




CN-AML patients are classified into the Favorable or the Intermediate-I ELN Genetic 
Group based on the mutational status of the CEBPA, NPM1 and FLT3 genes.11 The 
ELN Favorable Genetic Group comprises CN-AML patients with CEBPA mutation 
and/or NPM1 mutation that do not have internal tandem duplications of the FLT3 gene 
(FLT3-ITD), whereas the Intermediate-I Genetic Group encompasses CN-AML patients 
with wild-type CEBPA and either NPM1 mutation with FLT3-ITD or wild-type NPM1 
and/or FLT3-ITD.11 
 
Today reporting systems like the ELN system may also aid in the task of risk 
stratification and may help guiding the physician to choose the most appropriate 
treatment option.18 Furthermore, much effort has been undertaken to pharmacologically 
ELN Genetic Group Subsets 
Favorable 
t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13q22) or t(16;16)(p13q;22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Mutated CEBPA (normal karyotype) 
Intermediate-I 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
Intermediate-II 
t(9;11)(p22;q23); MLLT3-MLL 
Cytogenetic abnormalities not classified as favorable or adverse 
Adverse 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
-5 or del(5q); -7; abnl(17p); complex karyotype 
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target some of these molecular markers (e.g. alterations of the FLT3 gene), thereby 
leading to new treatment avenues in AML.19 
 
However, the limitations of today’s prognostic assessment and treatment approaches 
are reflected by the fact that only approximately 30% of all newly diagnosed AML 
patients survive in the long term.1,2,18 The outcome is even more dismal in older patients 
(≥60 years), who represent a large group of AML patients. Among them, only 
approximately 7 to 15% achieve long-term survival.1,2,18 Thus, novel markers are 
needed to improve identification of those patients that would be better served with more 
intense or experimental treatment approaches. Furthermore the identification of new 
molecular alterations would increase the understanding of the disease biology and aid 
in finding novel, targetable pathways in AML. Ultimately this in turn could lead to new 
treatment approaches for those patients that fail current therapeutic strategies, as 
demonstrated by the development of therapies targeting aberrant FLT3 activation in 
AML.19  
 
In addition to mutational markers, certain aberrantly expressed genes have been 
associated with outcome in AML patients (e.g. the expression of the BAALC, ERG or 
MN1 gene).20-31 The measurement of the expression levels of genes or of a panel of 
genes may harbor the advantage that potentially several different mutations or 
epigenetic events funnel into the net expression of a certain gene or gene panel. Thus 
the determination of expression levels of genes could substitute for investigating 
multiple genes for the presence of mutations and/or epigenetic changes. Once 
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standardized methods to quantify the expression levels of RNAs have been developed 
these expression markers might be able to provide a practical and financial advantage 
over the determination of multiple mutations in the future. 
 
Recently the differential expression of so called microRNAs (miRs) have been shown to 
be deeply involved in the development and maintenances of a variety of human 
cancers, including AML.32-42 MicroRNAs are short (on average 18-24 nucleotide long) 
non-coding RNA molecules that hybridize to their target messenger RNAs (mRNAs) and 
repress the expression of the encoded proteins.32,33 The mature miRs are derived from 
precursor molecules that are transcribed from their respective encoding genomic DNA 
sequences similarly to other coding mRNA molecules. Following processing of the 
precursor molecules the mature miRs are incorporated into the RNA-induced silencing 
complex (RISC) in which the miR and the respective targeted mRNA interact, which 
ultimately leads to a decreased expression of the encoded protein.32,33 
 
In AML expression-signatures of miRs have been associated with certain cytogenetic 
aberrations,36-42 as well as recurrent mutations, such as the afore mentioned alterations 
of the NPM1,38,41 FLT338 and CEBPA43 genes. Furthermore, it has been demonstrated 
that deregulated miR expression may also associate with outcome of CN-AML 
patients.36,42 Using miR-expression profiling in CN-AML patients with unfavorable 
molecular features (i.e. the presence of FLT3-ITD and/or NPM1 wild-type) a prognostic 
miR-signature was discovered.36 However, to our knowledge, the independent 
prognostic impact of expression levels of a single miR outside of miR-expression 
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profiles, which would be easier to measure for molecular risk assessment of individual 
patients has not been demonstrated in AML so far. Among the miRs in the described 
signature, the upregulation of the miR-181 family associated with favorable outcome in 
these molecular high-risk CN-AML patients.36 Interestingly, miR-181a has also been 
associated with certain morphological sub-types of AML cases.44 Thus to us miR-181a 
appeared to be a very promising candidate to pursue further investigations regarding its 
individual use for risk assessment. The genes encoding miR-181a and its close relative 
miR-181b are located in two clusters in close proximity on chromosome 1q32.1 and 
chromosome 9q33.3 of the human genome. In order to gain an impression of the 
differential miR-181a expression in AML patients, we measured the expression of the 
two precursor molecules miR-181a-1 (derived from chromosome 1q32.1) and miR-
181a-2 (derived from chromosome 9q33.3) in bone marrow samples of 75 AML patients 
with pretreatment material available that were enrolled on treatment protocols of the 
Ostdeutsche Studiengruppe für Hämatologie und Onkologie (OSHO) at the University of 
Leipzig. All of the enrolled patients received allogeneic hematopoietic cell 
transplantation after reduced-Intensity conditioning. The expression of the two 
precursors showed a good correlation (R2=0.8377, Figure 1A), which allowed us to use 
the mean expression of the two precursors for our preliminary investigation. At the time 
of this preliminary analysis, outcome data for a subset (n=22) of these 75 patients 
following the allograft procedure was available. Using a median cut to define low and 
high expressers of miR-181a, we analyzed the event-free survival (EFS) following 
allogeneic transplantation. Even though no statistical significance was reached, likely 
due to the limited number of patients with outcome data available at the time of 
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analysis, we observed a very promising trend (P=.07; log-rank test) towards a longer 
EFS following the allogeneic transplantation for patients that expressed miR-181a at 









Figure 1:  A) Scatter plot of relative miR-181a-1 and miR-181a-2 expression, normalized to 18S in 
pretreatment bone marrow samples of 75 AML patients treated at the University of Leipzig. B) Event-free 
survival of a subset (n= 22) with outcome data available following the allogeneic transplantation according 
to miR-181a expression levels. 
 
These data provided initial support for the usefulness of the expression level of this 
individual miR to predict outcome in AML.  
In the here presented study we asked the question whether the expression levels of a 
single miR could provide prognostic information in CN-AML patients independent of a 















































































Zusammenfassung / Conclusion 
 
Within the scope of this thesis we present a study that reported on the prognostic 
impact of the expression levels of a single miR - miR-181a - in CN-AML patients. We 
showed that higher levels of miR-181a expression directly correlated with higher odds of 
achieving CR following standard cytarabine/daunorubicine based treatment protocols 
and lower risk of experiencing relapse and/or death. This is - to our knowledge - the first 
study that demonstrated that the expression of a single non-coding RNA associates with 
clinical outcome in AML, even in the context of other well established molecular 
markers. In the manuscript we also validated our results in an independent set of older 
(≥60 years) CN-AML patients. Higher miR-181a expression levels were also associated 
with a significantly higher CR rate, and longer disease-free (DFS) and overall survival 
(OS) within the ELN Intermediate-I Genetic Group, thus refining the ELN risk 
classification. Altogether, the presented data support a pivotal role of miR-181a 
expression levels for the response to treatment of CN-AML patients, and suggest that 
miR-181a expression might be used to further refine the risk in AML patients.11 
Additional studies to validate our prognostic findings are needed. Interestingly, very 
recently the favorable prognostic impact of higher miR-181 could also be shown to in 
AML with cytogenetic abnormalities.45 Moreover, validation studies are currently ongoing 
at the University of Leipzig, building upon our preliminary data (shown in the 
introduction) that suggest that higher pretreatment expression levels of miR-181a may 
also be associated with improved outcome following allogeneic hematopoietic cell 
transplantation after reduced-Intensity conditioning. If the results are confirmed and 
validated and once standardized RNA quantification methods are established, miR-
32 
181a expression might be included in diagnostic panels, and used to improve risk-
stratification of AML patients and help guide treatment decisions of physicians.  
 
Additionally, in the here presented study, in order to gain insight into the biology of miR-
181a associated leukemia, we derived a genome-wide gene expression profile 
associated with miR-181a expression levels. These results may aid in the task of 
elucidating the biology of miR-181a associated outcome differences in CN-AML 
patients, and provide a basis for further functional studies.  
 
Since our prognostic study was published, additional evidence that underscore miR-
181a’s tumor suppressive effects and thus support our findings have emerged. In 
chronic lymphatic leukemia (CLL) lower miR-181a expression levels have been 
associated with a more aggressive subtype harboring chromosome 17p deletions and in 
gastric cancer higher miR-181 expression was reported to be associated with increased 
chemosensitivity.46,47 Furthermore, recently other groups have reported targets of miR-
181a that may also have a role in AML. Shin et al. demonstrated that miR-181a may 
have tumor suppressor activity by targeting oncogenic K-Ras in oral squamous 
cancer,48 and it has been described that high expression levels of miR-181a promote 
apoptosis in gliomas and astrocytomas by targeting members of the BCL2 family.49,50 
Indeed, also BCL2 itself has been suggested to be a direct target of miR-181a and Bai 
et al. showed that miR-181a directly targets anti-apoptotic BCL2 in AML cell lines.51,52 
Overexpression of miR-181a in a cytarabine resistant HL-60 cell line decreased BCL-2 
expression, induced apoptosis and sensitized the cells to cytarabine treatment.52 The 
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findings that miR-181a is able to lower the endogenous apoptosis threshold of AML 
blasts supports our observation of an association of higher miR-181a expression with 
treatment response in AML and provided a functional basis for our clinical observations. 
  
The identification of low levels of miR-181a as an adverse prognostic factor provides the 
opportunity for potential therapeutic intervention by artificially substituting miR-181a. 
Since free synthetic miRs are easily degraded in bio-fluids, have limited cellular uptake 
and are quickly cleared from blood the administration of unprotected synthetic miRs 
does not present a feasible approach. However, we recently presented a novel non-viral 
nanoparticle based targeted delivery system for miRs in AML, which may overcome 
these limitations.53 In a proof-of-principal study, our preliminary results indicated that our 
nanoparticle-based delivered synthetic miR-181a is efficient in upregulation of mature 
miR-181a levels in AML cell lines and patient blasts. These increased miR-181a levels 
consequently downregulated miR-181a target genes (i.e. NRAS and KRAS) in miR-
181a-nanoparticle treated AML cells.53 Furthermore, the miR-181a-nanoparticle 
treatment had anti-leukemic activity and sensitized AML blasts to daunorubicine 
treatment in vitro,53 which is in accordance with the findings in the here presented 
clinical study as well as the in vitro findings reported by others. These results show that 
miR-181a may not only have prognostic significance and improve risk stratification in 
AML, but our findings may also pave the way to a new miR-based personalized 
medicine for AML patients in the future. 
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